INDSWFTLAB · Concall Summary
IND SWIFT LABORATORIES LT
Ind-Swift Laboratories Limited held its Q1 FY27 earnings conference call on August 17, 2026, to discuss its operational and financial performance for the quarter ended June 30, 2026. Management reported a strong start to the year, highlighting a transformation from an API player to a focused Finished Dosage Formulation (FDF) manufacturer. Key operational developments included the commercialization of CDMO partnerships with Viatris, Manx, and Arrotex, projected to contribute ₹200 to ₹220 crore in FY27. The company launched two new products and increased its global product registrations to over 850. Financially, operating income grew 21.16% year-on-year to ₹186.08 crore, with operating EBITDA improving 2.85x to ₹33.32 crore. PAT excluding exceptional items rose to ₹24.68 crore, reflecting a significant year-on-year increase. Management expressed confidence in sustaining this operational momentum throughout FY27.
Management emphasized strong operational and financial performance during the quarter.
View source filing →Earlier concalls
- 2026-08-17 — Ind-Swift Laboratories Limited reported strong financial results for Q1 FY27, with operating EBITDA increasing 2.85 time…
- 2026-02-04 — Ind-Swift Laboratories Limited reported stable revenue for Q3 FY26, with a 6.60% increase in Operating EBITDA and a 22.6…
See INDSWFTLAB's full Research Pro page — annual report summary, insider trades, promoter pledge trend, options positioning and Ask-RedixFi AI.
Sign up free